The Late-Breaking Clinical Trial submission portal will open on June 1 for VIVA and The VEINS 2022. To be added to our mailing list and receive future updates, please email firstname.lastname@example.org.
We are pleased to announce that The VEINS 2022 will offer a venous-focused series of Late-Breaking Clinical Trials in addition to the late-breaking presentation series at VIVA. Learn more about these sessions and abstract requirements below:
Physicians and researchers will present groundbreaking findings from late-breaking clinical trials, follow-up data from major randomized trials and registries, and first-in-man experiences with novel devices or drugs.
A limited number of abstracts will be accepted for presentation. Accepted late-breaking clinical trials will be presented on Monday, October 31 (The VEINS) and Tuesday-Wednesday, November 1-2 (VIVA). Each presentation will be followed by a discussion and Q&A with a panel of expert faculty.
The abstract submission deadline is Wednesday, August 10, at 5pm PT.
Research must be original and may not have been presented prior to the Late-Breaking Clinical Trial sessions at VIVA and The VEINS 2022. Abstracts must be submitted electronically via the official late-breaking submission website.
Abstract submissions should address areas of endovascular intervention and medicine and can report the results of basic science investigations as well as clinical or pre-clinical studies.
Abstracts must include:
The total abstract length may not exceed 2,500 characters, exclusive of title or figures. The following information must be provided upon submission:
The 2022 submission portal will open on June 1 and close on August 10. Abstracts will be scored after the submission deadline and will be evaluated and scored based on the following criteria:
Notification of acceptance or rejection will be sent the week of August 22, 2022. Subsequent communication will provide specifics about submitting the presentation and the date and time of the presentation.
If you have questions please contact Brita Thorne via e-mail: email@example.com
VIVA embargoes Late-Breaking Clinical Trial information from becoming public until after the commencement of the session as listed in the conference program or on viva-foundation.org. No publication, exhibitor, or affiliated company may disseminate information until after the commencement of the Late-Breaking Clinical Trial session in which it is presented.
The Late-Breaking Clinical Trial submission portal will reopen on June 1, 2022. To be added to our mailing list and receive future updates, please email firstname.lastname@example.org.